Clinical Trials to Compare Mosapride Bioavailability Between DWJ1252 and Mosapride Medicine
Launched by DAEWOONG PHARMACEUTICAL CO. LTD. · Mar 26, 2010
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • a healthy adult male within the range of 20 to 50 years old at the time of screening
- • with weight of more than 55kg, in the range of IBW 20%: IBW(kg)={height(cm)-100}\*0.9
- • who understood completely about this study after the detailed explanation is given, decided to volunteer and gave written informed consent to participate in study in compliance with the requirement of the entire protocol.
- Exclusion Criteria:
- • one with clinically significant disease in liver, kidney, nerve system, respiratory system, endocrine system, blood, tumor, urinary system, cardiovascular system, mental disease or with medical history
- • one with gastrointestinal disease or with gastrointestinal surgical history which can affect the absorption of the investigational drug.
- • one with genetic disease like galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- • one who is allergic or has clinically significant allergic history to the component of the investigational drug (mosaprisde), and any component from same family, or to other drugs(Aspirin, antibiotics, etc)
- • one who shows different rhythm than sinus rhythm in screening, like QTc \>450ms on electrocardiogram, PR interval\>200msec or QRS interval 120\>msec
- • one who shows the following result in clinical laboratory test: AST,ALT\>1.25 times of the upper limit of normal range
- • one who shows vital signs with the number of systolic blood pressure of 160 mmHg or 100 mmHg, and the number of diastolic blood pressure of 95mmHg or 60mmHg
About Daewoong Pharmaceutical Co. Ltd.
Daewoong Pharmaceutical Co., Ltd. is a leading South Korean biopharmaceutical company committed to advancing healthcare through innovative research and development. With a strong focus on the discovery and commercialization of novel therapeutics, Daewoong specializes in a diverse range of therapeutic areas, including gastroenterology, endocrinology, and neurology. The company is dedicated to improving patient outcomes by leveraging cutting-edge technology and scientific expertise, and it actively engages in global clinical trials to bring new treatments to market. Daewoong's commitment to quality and innovation positions it as a key player in the pharmaceutical industry, striving to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Kyung-Sang Yu
Principal Investigator
Seoul National University Hospital IRB
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials